Details for Patent: 10,849,916
✉ Email this page to a colleague
Which drugs does patent 10,849,916 protect, and when does it expire?
Patent 10,849,916 protects FRINDOVYX and is included in one NDA.
This patent has one patent family member in one country.
Summary for Patent: 10,849,916
| Title: | Stable liquid formulations of cyclophosphamide and its impurities |
| Abstract: | The present invention relates to novel impurities of cyclophosphamide having structure V, VI or VII, stabilized form of these novel impurities, a process of preparing a stabilized form and isolating thereof. The invention also relates cyclophosphamide formulations which include cyclophosphamide, at least one pharmaceutically acceptable excipient, and a certain level of these impurities having structure V, VI or VII. The invention further relate to method of using such stable liquid formulations of cyclophosphamide for parenteral administration in treating various cancer disorders. |
| Inventor(s): | Riyaz Ahmed Shaik, Ananya SAHA, SVB Janardhan Garikipati, Akash CHAURASIYA, Bhavesh Vallabhbhai PATEL, Harshal BHAGWATWAR, Sumitra Ashok Pillai, Satheesh Balasubramanian, Joydeep MAZUMDER |
| Assignee: | Avyxa Holdings LLC |
| Application Number: | US16/414,418 |
|
Patent Claim Types: see list of patent claims | Composition; Formulation; Compound; |
Drugs Protected by US Patent 10,849,916
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Avyxa Holdings | FRINDOVYX | cyclophosphamide | SOLUTION;INTRAVENOUS | 210852-002 | Jun 7, 2023 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| Avyxa Holdings | FRINDOVYX | cyclophosphamide | SOLUTION;INTRAVENOUS | 210852-003 | Jun 7, 2023 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| Avyxa Holdings | FRINDOVYX | cyclophosphamide | SOLUTION;INTRAVENOUS | 210852-001 | Jun 7, 2023 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 10,849,916
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| World Intellectual Property Organization (WIPO) | 2016005962 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
